The Fractalkine Receptor CX
Aged
Biomarkers
CX3C Chemokine Receptor 1
/ genetics
Cytomegalovirus
Cytomegalovirus Infections
/ complications
Female
Heart Function Tests
Humans
Immunophenotyping
Lymphocytes
/ immunology
Magnetic Resonance Imaging
Male
Middle Aged
Myocardial Infarction
/ complications
Receptors, CCR7
/ metabolism
Ventricular Remodeling
/ genetics
CX3CR1
T-lymphocytes
acute myocardial infarction
cardiac MRI
cytomegalovirus
remodeling
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
13
09
2020
accepted:
20
04
2021
entrez:
28
5
2021
pubmed:
29
5
2021
medline:
1
7
2021
Statut:
epublish
Résumé
Latent cytomegalovirus (CMV) infection is associated with adverse cardiovascular outcomes. Virus-specific CX We retrospectively analysed lymphocyte count, troponin, and survival in 4874 STEMI/pPCI patients, evaluated lymphocyte kinetics during reperfusion in a prospective cohort, and obtained sequential cardiac MRI (cMRI) to assess remodeling. Pre-reperfusion lymphopenia independently predicted mortality at 7.5 years. Prior to reperfusion, CCR7 We show that lymphopenia occurs before and after reperfusion in STEMI by different mechanisms and predicts long-term outcome. In CMV+ patients, increased fractalkine induction and sequestration of CX
Identifiants
pubmed: 34046028
doi: 10.3389/fimmu.2021.605857
pmc: PMC8147691
doi:
Substances chimiques
Biomarkers
0
CCR7 protein, human
0
CX3C Chemokine Receptor 1
0
CX3CR1 protein, human
0
Receptors, CCR7
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
605857Subventions
Organisme : British Heart Foundation
ID : FS/15/77/31823
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/18/25/33587
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Informations de copyright
Copyright © 2021 Spray, Park, Cormack, Mohammed, Panahi, Boag, Bennaceur, Sopova, Richardson, Stangl, Rech, Rainer, Ramos, Hofmann, Stellos and Spyridopoulos.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Pharmacol. 2019 May;59(5):688-701
pubmed: 30575978
Br J Clin Pharmacol. 2020 Jul;86(7):1387-1397
pubmed: 32067256
JACC Cardiovasc Imaging. 2014 Sep;7(9):930-9
pubmed: 25212799
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
N Engl J Med. 2019 Feb 21;380(8):752-762
pubmed: 30415610
Circulation. 2005 Mar 1;111(8):1027-32
pubmed: 15723982
N Engl J Med. 2015 Sep 10;373(11):1021-31
pubmed: 26321103
Proc Natl Acad Sci U S A. 2017 Mar 21;114(12):E2420-E2429
pubmed: 28255084
J Am Heart Assoc. 2017 Jul 6;6(7):
pubmed: 28684641
Exp Physiol. 2015 Jul 1;100(7):805-17
pubmed: 25943588
Blood. 2008 Jan 1;111(1):175-82
pubmed: 17895402
Mol Interv. 2010 Oct;10(5):263-70
pubmed: 21045240
PLoS One. 2012;7(10):e47155
pubmed: 23077561
N Engl J Med. 2019 Dec 26;381(26):2497-2505
pubmed: 31733140
JACC Cardiovasc Interv. 2008 Aug;1(4):415-23
pubmed: 19463339
Immunology. 2011 Mar;132(3):326-39
pubmed: 21214539
Nature. 1999 Oct 14;401(6754):708-12
pubmed: 10537110
Aging Cell. 2016 Apr;15(2):389-92
pubmed: 26696322
Nat Rev Immunol. 2008 May;8(5):362-71
pubmed: 18379575
Blood. 2007 Sep 15;110(6):1857-63
pubmed: 17519388
J Am Coll Cardiol. 2014 Sep 23;64(12):1217-26
pubmed: 25236513
Circ Res. 2015 Jan 2;116(1):87-98
pubmed: 25385851
Arterioscler Thromb Vasc Biol. 2012 Sep;32(9):2206-13
pubmed: 22796582
Arterioscler Thromb Vasc Biol. 2005 Dec;25(12):2567-72
pubmed: 16224053
J Immunol. 2004 Aug 1;173(3):1834-41
pubmed: 15265915
J Clin Invest. 2015 Aug 3;125(8):3063-76
pubmed: 26168217
Am J Pathol. 2010 May;176(5):2177-87
pubmed: 20382703
Circulation. 2009 Oct 6;120(14):1364-72
pubmed: 19770396
J Virol. 2004 Dec;78(23):13173-81
pubmed: 15542669
Circulation. 2000 Nov 7;102(19):2335-40
pubmed: 11067785